# The Adaptive COVID-19 Treatment Trial (ACTT)

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $25,075,500

## Abstract

To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.

## Key facts

- **NIH application ID:** 10330399
- **Project number:** 75N91019D00024-P00004-759102000010-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** BETH BASELER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $25,075,500
- **Award type:** —
- **Project period:** 2020-04-03 → 2025-04-02

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10330399

## Citation

> US National Institutes of Health, RePORTER application 10330399, The Adaptive COVID-19 Treatment Trial (ACTT) (75N91019D00024-P00004-759102000010-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10330399. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*